“…Human primary dendritic cells as well as myeloid cell lines are used in in vitro approaches to predict skin sensitization (Basketter et al, 2008;Ott et al, 2010;Python et al, 2009), e.g., the Myeloid U937 Skin Sensitization Test (MUSST), which measures increase of CD86 expression (Ade et al, 2006;Python et al, 2007), the human Cell Line Activation Test (h-CLAT), which assesses increase of CD86 and combined CD54 expression (Sakaguchi et al, 2006), or the Genomic Allergen Rapid Detection (GARD), which is based on a signature of predictive genes differentially regulated in the MUTZ3 cell line when stimulated with sensitizing compared to non-sensitizing compounds (Johansson et al, 2013).…”